5:43 PM
Mar 25, 2013
 |  BC Extra  |  Company News

Boehringer submits empagliflozin NDA

Boehringer Ingelheim GmbH (Ingelheim, Germany) submitted an NDA to FDA for empagliflozin to treat...

Read the full 54 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >